Paul Edwards Posted December 26, 2015 Share Posted December 26, 2015 The New Prostate Cancer Infolink reports Full data on ADT + chemotherapy from the STAMPEDE trial now published The report has links to the full text of articles in the Lancet regarding this research. "For men with metastatic prostate cancer starting [androgen deprivation] therapy for the first time, we found strong evidence to support the addition of docetaxel to androgen deprivation therapy as the new standard of care, and this combination should be offered to men who are fit to receive chemotherapy. " There is no sufficient evidence yet to recommend docetaxel plus androgen deprivation therapy for hormone-naive men men diagnosed with micrometastatic prostate cancer (cancer in the lymph nodes but not yet metastasised to the bone - M0) Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.